Journal
DERMATOLOGIC THERAPY
Volume 33, Issue 6, Pages -Publisher
WILEY
DOI: 10.1111/dth.14097
Keywords
monotherapy; pityriasis rubra pilaris; secukinumab
Categories
Funding
- Natural Science Foundation of Guangdong [2018A0303130011]
- Science and Technology Program of Guangzhou [201904010191]
- Characteristic Clinic Project of Guangzhou Health Commission [2019TS68]
Ask authors/readers for more resources
Pityriasis rubra pilaris (PRP) is a rare heterogeneous group of papulosquamous inflammatory disorders with unknown etiology. PRP is often resistant to many conventional therapies which has made more challenging on treatment. More recently, several studies have shown encouraging clinical results of secukinumab in the treatment of PRP in adult, but no studies have explored its effects in children. We herein report a 7-year-old boy with severe type V PRP responded rapidly to secukinumab monotherapy (150 mg once weekly) when conventional therapies have failed. The patient showed rapid and dramatic improvement of erythema, palmoplantar hyperkeratosis, scaling, and itching within only 5 weeks, with no adverse effects. Secukinumab could be considered as a treatment option for refractory PRP in children, as recently reported in adult.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available